Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal seamless Phase 1/2 clinical trial of GC007g for the treatment of r/r B-cell acute lymphoblastic leukemia (B-ALL)

Next Previous
X
Search
Trial Profile

A pivotal seamless Phase 1/2 clinical trial of GC007g for the treatment of r/r B-cell acute lymphoblastic leukemia (B-ALL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GC 007g (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Gracell Biotechnology

    • Most Recent Events

    • 15 May 2023 According to a Gracell Biotechnology media release, between March 2021 and May 2022, nine r/r B-ALL patients were enrolled and treated in the Phase 1 portion of the registrational Phase 1/2 clinical trial at two different dose levels.
    • 15 May 2023 According to a Gracell Biotechnology media release, phase 1 data will be presented at the EHA2023.
    • 13 Mar 2023 According to a Gracell Biotechnology media release, phase 2 portion of the registration of this phase 1/2 trial is ongoing.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top